Long COVID top news

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Fluconazole prophylaxis improves overall survival in AML patients

Publish date:: July 22, 2020

Key clinical point: Acute myeloid leukemia patients had less IFI with fluconazole prophylaxis.

Major finding: Overall survival at 60 days was improved in with fluconazole prophylaxis compared

with no prophylaxis (HR, .329; P = .028).

Study details: A retrospective, interrupted time series study of 144 AML induction patients with and without fluconazole prophylaxis.

Disclosures: The authors reported that they had no conflicts of interest.

Citation:

Signorelli J et al. Clinical Lymphoma, Myeloma and Leukemia. 2020; doi.org/10.1016/j.clml.2020.06.008.

This Week's Must Reads

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

COVID-19–induced drop in first measles vaccinations sparks resurgence concerns,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Three genes could predict congenital Zika infection susceptibility,

‘Excellent short-term outcomes’ seen in HCV+ liver transplants to HCV– recipients,

Must Reads in Invasive fungal infections

Posaconazole prophylaxis was effective in children with ALL undergoing chemotherapy,

Infection with Fusarium is a risk in hematology patients,

Primary immunodeficiency disease patients have high risk of invasive fungal disease,

MicroRNAs can distinguish invasive aspergillosis in lung transplant recipients,

Saliva-controlled sputum culture aids diagnosis of deep pulmonary infections,